Evidence map›Paper›PMID 38264719›Full record

ArticlePatterns (New York, N.Y.)2024

AlphaML: A clear, legible, explainable, transparent, and elucidative binary classification platform for tabular data.

Ahmad Nasimian, Saleena Younus, Özge Tatli, Emma U Hammarlund, Kenneth J Pienta, Lars Rönnstrand, Julhash U Kazi

Abstract read
In one paragraph

Article in Patterns (New York, N.Y.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Ahmad NasimianDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Saleena YounusDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Özge TatliDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Emma U HammarlundLund Stem Cell Center, Lund University, Lund, Sweden.
Kenneth J PientaThe Cancer Ecology Center, Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, MD, USA.
Lars RönnstrandDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.
Julhash U KaziDivision of Translational Cancer Research, Department of Laboratory Medicine, Lund University, Lund, Sweden.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Leveraging the potential of machine learning and recognizing the broad applications of binary classification, it becomes essential to develop platforms that are not only powerful but also transparent, interpretable, and user friendly. We introduce alphaML, a user-friendly platform that provides clear, legible, explainable, transparent, and elucidative (CLETE) binary classification models with comprehensive customization options. AlphaML offers feature selection, hyperparameter search, sampling, and normalization methods, along with 15 machine learning algorithms with global and local interpretation. We have integrated a custom metric for hyperparameter search that considers both training and validation scores, safeguarding against under- or overfitting. Additionally, we employ the NegLog2RMSL scoring method, which uses both training and test scores for a thorough model evaluation. The platform has been tested using datasets from multiple domains and offers a graphical interface, removing the need for programming expertise. Consequently, alphaML exhibits versatility, demonstrating promising applicability across a broad spectrum of tabular data configurations.

Indexed as

deep tabular learningdrug sensitivity predictionensemble learningexplainable AIfeature selectionhyperparameter optimizationmachine learningprecision medicineTabNetXGBoost

Identifiers

PMID38264719
PMCPMC10801203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.